Table 2 First- and second-line H. pylori treatment effectiveness in the younger and older European populations.

From: Comparison of the management of Helicobacter pylori infection between the older and younger European populations

Treatment

Younger adults (18–59 years)

Older adults (≥ 60 years)

Use, N

PP % (95% CI)

mITT % (95% CI)

ITT % (95% CI)

Use, N

PP % (95% CI)

mITT % (95% CI)

ITT % (95% CI)

Effectiveness of first-line treatment prescriptions between the younger and older populations

 Triple PPI + C + A

10,540

87 (86–87)

86 (85–87)*

67 (66–68)*

4065

88 (87–89)

87 (86–89)*

71 (69–72)*

 Triple PPI + C + M

1150

86 (84–88)

86 (83–88)

68 (65–71)

491

83 (79–86)

83 (79–86)

71 (66–75)

 Triple PPI + A + L

425

83 (79–87)

83 (78–86)

76 (72–80)

162

83 (75–88)

83 (76–89)

76 (69–82)

 Quadruple PPI + C + A + M

4199

90 (89–91)*

89 (88–90)*

86 (85–87)*

1940

91 (90–93)*

91 (90–92)*

89 (87–90)*

 Quadruple PPI + C + A + B

3489

92 (91–93)

92 (91–93)

76 (75–77)

1086

91 (89–93)

90 (88–92)

76 (73–79)

 Quadruple PPI + C + A + T

309

98 (95–99)

96 (93–98)

92 (88–95)

127

96 (89–99)

92 (85–96)

86 (78–92)

 Pylera® (single capsule)1

3233

94 (93–95)

93 (92–94)

89 (87–90)

1519

94 (93–95)

93 (92–95)

89 (87–91)

 Sequential C + A + T

1291

90 (88–92)*

90 (88–91)*

80 (78–82)*

623

94 (92–96)*

94 (91–96)*

85 (81–87)*

 Sequential C + A + M

458

84 (80–87)

82 (78–86)

76 (72–80)

222

84 (78–89)

82 (76–87)

75 (69–81)

Effectiveness of second-line treatment prescriptions between the younger and older populations

 Triple PPI + A + L

1422

83 (80–85)

82 (80–84)

74 (71–76)

524

80 (76–84)

80 (76–83)

73 (69–77)

 Triple PPI + C + A

323

78 (72–83)

78 (72–83)

60 (54–65)

102

84 (74–91)

84 (74–91)

68 (58–77)

 Triple PPI + A + R

105

80 (70–87)

79 (69–87)

68 (58–76)

49

82 (67–92)

82 (67–92)

74 (59–85)

 Triple PPI + A + Mx

105

92 (85–97)

92 (85–97)

90 (82–95)

35

87 (70–96)

87 (70–96)

77 (60–90)

 Quadruple PPI + A + L + B

584

89 (86–92)

89 (86–91)

73 (69–76)

225

86 (80–91)

86 (80–91)

75 (69–81)

 Quadruple PPI + C + A + M

234

84 (79–89)

84 (78–88)

80 (74–85)

91

86 (77–92)

86 (77–93)

83 (73–90)

 Quadruple PPI + M + Tc + B

224

86 (80–91)

84 (78–88)

75 (69–81)

101

87 (78–93)

88 (79–94)

77 (68–85)

 Quadruple PPI + C + A + B

229

91 (85–96)*

91 (85–95)*

52 (45–59)

66

79 (64–89)*

80 (66–90)*

60 (47–72)

 Pylera® (single capsule)1

843

89 (87–91)

89 (86–91)

83 (80–86)*

384

92 (89–95)

91 (88–94)

88 (84–91)*

  1. PP—per protocol, mITT—modified Intention-To-Treat, ITT—Intention-To-Treat, 95% CI—95% confidence interval, PPI—proton pump inhibitor, C—clarithromycin, A—amoxicillin, M—metronidazole, B—bismuth, T—tinidazole, L—levofloxacin, Tc—tetracycline, Mx—moxifloxacin, R—rifabutin.
  2. 1Pylera®: three-in-one single-capsule containing metronidazole, tetracycline and bismuth.
  3. *Statistically significant differences between the age groups, p < 0.05.
Back to article page